Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > Proof of old adage. Bad news travels third class

<< Previous

Bullboard Posts

Next >>

Comment by Majictraderon Jan 18, 2021 5:26pm

157 Views

Post# 32322653

RE:RE:RE:Proof of old adage. Bad news travels third class

Agreed. Own vxl for a while now. Will take some money near the upcoming event :). Cph still have quite a bit after the cut as well, so will hold. I think there should be some clarity on marketing n all now that this episode is somewhat over. If bausch was looking to buy them out then 1.50 or 1.25 is what cph holder may get. Else we wait for good news on US sales n marketing partner. Lesson, keep taking profits :). Good luck all.

<< Previous

Bullboard Posts

Next >>

Golden Minerals closes Yoquivo gold-silver project sale